Genome Editing/Genome Engineering Market by Technology (CRISPR, TALEN, ZFN), Application (Cell Line Engineering & Genetic Engineering), End User (Research Centers, Pharmaceutical & Biotechnology Companies, CROs) - Analysis & Forecast 2019-2030
Report ID : 5 | Published Date : Jan 2019 | Pages : 150 | Region : Global | Report Code : BT-01
Genome Editing/Genome Engineering Market Overview and Introduction
Genome Editing/Genome Engineering technique are used for insertion, deletion or modify genome of a microorganism. Techniques like TALEN, CRISPR (clustered regularly interspaced palindromic repeat) and other technique are widely used in genome editing/engineering process. CRISPR-Cas9 technique is one of the most widely preferred technologies in genome editing.
The global genome editing/genome engineering market is driven by technological advancements in the genomics, rising number of cancer patients, and increasing funding by government & private players in the genomics are major factors driving the market. However, ethical issue related to genome editing/genome engineering is likely to restrain the market to certain extent.
Genome Editing/Genome Engineering Market by Application, Technology and End Users
The global genome editing/genome engineering market is segmented by application, technology, end user, and region. Based on technology, the market is segmented into TALEN, CRISPR, ZFN and other technologies. The CRISPR technologies market is estimated to account for the largest share of the global genome editing/genome engineering market. The large share of this segment can be attributed to growing acceptance of the technology, government funding to promote genome research projects and focus to produce genetically modified crops. On the basis of end user, the Genome Editing/Genome Engineering Market is segmented into Pharmaceutical & Biotechnology Companies, Academic & Research Institutes Contract Research Organizations, and other end users. The Pharmaceutical & Biotechnology Companies segment is estimated to account for the largest share of the genome editing/genome engineering market. Increasing number of cancer cases globally and need for genome research are driving the growth of end-user segment. On the basis application the market is segmented into cell line engineering, genetic engineering and other applications. Cell line engineering is expected to account for the largest share of the segment. Factors such as, growing focus on stem cell technology and government & private funding in the research area are likely to drive the market for genome editing/genome engineering market.
Genome Editing/Genome Engineering Market by Regions
The global genome editing/genome engineering market can be segmented into North America, Europe, Asia Pacific, and Rest of World (ROW). North America dominated the market of genome editing/genome engineering, followed by Europe and Asia Pacific. North America will continue to dominate the global genome editing/genome engineering market in the forecast period owing to factors such as growing research on stem cells and cell lines for cancer therapy, rising use of genetically modified crops and highly developed healthcare system and funding from government and private institute. However, Asia Pacific is expected to witness the highest CAGR, with the growth in this market centered at China, India, and Japan. Factors such as the rising focus of major players in emerging Asian countries and government support are driving the growth of the genome editing/genome engineering market in this region. However, Ethical issue related genome editing/genome engineering products and lack of skilled professionals may restrain market growth to a certain extent.
Genome Editing/Genome Engineering Market Prominent Players
The prominent players in the global genome editing/genome engineering market are Thermo Fisher Scientific (US), Lonza Group (Switzerland), Merck (Germany), Horizon Discovery Group (UK), Integrated DNA Technologies (US), New England Biolabs (US), GenScript (US), Sangamo BioSciences (US), OriGene Technologies (US), Transposagen Biopharmaceuticals (US), Editas Medicine (US), and CRISPR Therapeutics (Switzerland)., among others.